Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21634175 | 0.92 | MAPT (0.41) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL23278481 | 0.92 | MAPT (0.41) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL21216907 | 0.92 | MAPT (0.41) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL2936355 | 0.86 | — | — | |
| SCHEMBL26112475 | 0.86 | MAPT (0.45) | MAPTRAB9ASMN1; SMN2LMNAMEN1 | |
| SCHEMBL4771122 | 0.78 | MAPT (0.41) | MAPTNPC1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL9830433 | 0.77 | SMN1; SMN2 (0.47) | MAPTNPC1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL6004429 | 0.77 | TYMP (0.35) | MAPTNPC1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL26107571 | 0.77 | MAPT (0.41) | MAPTNPC1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL10396477 | 0.77 | TSHR (0.33) | MAPTNPC1TSHRRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215572-A1 | SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY | SHIKOKU CHEMICALS CORPORATION (JP) | 2025-07-03 | — | — | US | disclosed |
| EP-4506488-A1 | SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY | Shikoku Chemicals Corporation (JP) | 2025-02-12 | — | — | EP | disclosed |
| CN-118922584-A | Surface treating agent for copper or copper alloy | 四国化成工业株式会社 | 2024-11-08 | — | — | CN | disclosed |
| WO-2023190263-A1 | SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY | 四国化成工業株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-9947482-B2 | Photoelectric conversion element, dye-sensitized solar cell, and metal complex dye used in same | FUJIFILM CORPORATION (JP) | 2018-04-17 | — | — | US | disclosed |
| US-7132437-B2 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE (US) | 2006-11-07 | — | — | US | disclosed |
| US-20040220245-A1 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE & CO., | 2004-11-04 | — | — | US | disclosed |
| US-20040121989-A1 | such as methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE & CO. | 2004-06-24 | — | — | US | disclosed |
| EP-0527851-B1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | SEARLE & CO (US) | 1998-12-23 | — | — | EP | disclosed |
| EP-0527851-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1993-02-24 | — | — | EP | disclosed |
| WO-1992004335-A2 | RENAL-SELECTIVE BIPHENYLALKYL 1H-SUBSTITUTED-1,2,4-TRIAZOLE ANGIOTENSIN II ANTAGONISTS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1991017148-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220245-A1 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | GLS, AGTR1, AGTR2 | MAPT 4850/4885NPC1 4749/4885TSHR 1498/4885 |
| US-20040121989-A1 | such as methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | GLS, AGTR1, AGTR2 | MAPT 4832/4885NPC1 4699/4885TSHR 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.